<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00677053</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-442_202</org_study_id>
    <secondary_id>U1111-1112-5867</secondary_id>
    <nct_id>NCT00677053</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes</brief_title>
  <official_title>A Phase 2, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of multiple doses of
      TAK-442once daily, (QD) or twice daily (BID), in subjects with acute coronary syndrome
      (unstable angina, myocardial infarction).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute coronary syndrome, including myocardial infarction with or without ST-segment elevation
      and stable or unstable angina, is acknowledged to represent collectively a major global
      healthcare problem. Despite existing treatments, the rates of patient mortality, myocardial
      infarction and hospital readmissions during follow-up remain very high.

      Due to its critical role in propagating the blood coagulation cascade, activated factor X now
      is considered to be a major therapeutic target in the development of novel antithrombotic
      therapy by blocking thrombin generation and attenuating the formation of fibrin. Therefore,
      activated factor X inhibitors, exhibiting either indirect or direct modes of action, are
      among the novel agents under investigation in the treatment of acute coronary syndrome.

      This study will evaluate the safety and tolerability of TAK-442 compared with placebo in
      post-acute coronary syndrome subjects who are also receiving standard antiplatelet and other
      cardiovascular therapy.

      Individuals who want to participate in this study will be required to provide written
      informed consent. Study participation is anticipated to be approximately 3.5 months. Multiple
      procedures will occur at each visit which may include fasting, blood collection, urine
      collection, physical examinations, electrocardiograms and bilateral venogram.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Major Bleeding Events defined by the Thrombolysis in Myocardial Infarction Scale.</measure>
    <time_frame>On Occurrence (Up to 24 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of Cardiovascular Mortality, non-fatal Myocardial Infarction, non-fatal Stroke, or Myocardial Ischemia requiring hospitalization.</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Mortality.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal Myocardial Infarction.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal Stroke.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Ischemia requiring hospitalization.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic Mortality.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Cardiovascular death, non-fatal Myocardial Infarction, or Myocardial Ischemia requiring hospitalization.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Cardiovascular death, non-fatal Myocardial Infarction, or non-fatal Stroke.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for Heart Failure.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of minor bleeding events defined by the Thrombolysis in Myocardial Infarction Scale.</measure>
    <time_frame>On Occurrence (Up to 24 weeks).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of minimal bleeding events defined by the Thrombolysis in Myocardial Infarction Scale.</measure>
    <time_frame>On Occurrence (Up to 24 weeks).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of major, clinically significant non-major bleeding AND minor bleeding events as defined by the Secondary Bleeding Scale</measure>
    <time_frame>On Occurrence (Up to 24 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">2753</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>TAK-442 10 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Added with standard care for recurrent ischemic events.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-442 20 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Added with standard care for recurrent ischemic events</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-442 40 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Added with standard care for recurrent ischemic events</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-442 40 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Added with standard care for recurrent ischemic events</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-442 80 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Added with standard care for recurrent ischemic events</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-442 80 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Added with standard care for recurrent ischemic events</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-442 160 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Added with standard care for recurrent ischemic events</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-442 120 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Added with standard care for recurrent ischemic events</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Added with standard care for recurrent ischemic events</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-442</intervention_name>
    <description>Stage I: TAK-442 10 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>TAK-442 10 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-442</intervention_name>
    <description>Stage I: TAK-442 20 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>TAK-442 20 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-442</intervention_name>
    <description>Stage I: TAK-442 40 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>TAK-442 40 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-442</intervention_name>
    <description>Stage II: TAK-442 40 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>TAK-442 40 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-442</intervention_name>
    <description>Stage II: TAK-442 80 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>TAK-442 80 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-442</intervention_name>
    <description>Stage II: TAK-442 80 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>TAK-442 80 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-442</intervention_name>
    <description>Stage III: TAK-442 160 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>TAK-442 160 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-442</intervention_name>
    <description>Stage III: TAK-442 120 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>TAK-442 120 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Stages I, II &amp; III: TAK-442 placebo-matching capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has been hospitalized for acute coronary syndrome

          -  Is able to initiate study drug if:

               -  The index event occurred within the past 7 days (the date of initial
                  hospitalization will be utilized for the date on which the index event occurred),
                  and

               -  The final acute medical or cardiac procedural intervention for the treatment of
                  acute coronary syndrome was last administered or performed at least 36 hours
                  before administration of the first dose of study drug.

          -  Has at least 1 of the following additional ischemic risk factors:

               -  Previous myocardial infarction.

               -  The index event was an anterior myocardial infarction.

               -  Presence of multivessel coronary disease

               -  Left bundle branch block.

               -  Left ventricular ejection fraction less than 40% at any time during
                  hospitalization for the index event.

               -  Killip class greater than or equal to II at any time during hospitalization for
                  the index event.

               -  History of symptomatic congestive heart failure

               -  History of ischemic stroke or transient ischemic attack.

               -  Presence of peripheral arterial obstructive disease.

               -  Diabetes mellitus requiring medical therapy to maintain glycemic control.

               -  Current smoker

               -  Moderate renal impairment

          -  Females of childbearing potential who are sexually active must agree to use adequate
             contraception, and can neither be pregnant nor lactating from Screening throughout the
             duration of the study.

        Exclusion Criteria:

          -  Has low body weight greater than 50 kg.

          -  Has severe hypertension.

          -  Has a known bleeding/clotting disorder.

          -  Has acute pericarditis.

          -  Has a history of intracranial or intraocular bleeding.

          -  Has a history of gastrointestinal bleeding or gastric or duodenal ulceration.

          -  Has a history of ischemic stroke or transient ischemic attack.

          -  Has had major surgery, including coronary artery bypass graft or has undergone
             non-major laparoscopic surgery or non-major minimally invasive surgery, within 2 weeks
             prior to Randomization.

          -  Has a history of cancer that has not been in remission for at least 5 years.

          -  Has a condition for which long-term anticoagulation therapy is indicated or requires
             ongoing use of other excluded medications.

          -  Has severe renal dysfunction.

          -  Has anemia or thrombocytopenia that has not resolved prior to Randomization.

          -  Has alanine aminotransferase or total bilirubin levels greater than 2 times the upper
             limit of normal, active liver disease or jaundice.

          -  Has a history of illicit drug use or excessive alcohol intake.

          -  Has any other serious disease or condition that would compromise subject safety,
             increase the risk of bleeding, or make it difficult to successfully manage and follow
             the subject according to the protocol.

          -  Has received TAK-442 in a previous clinical study or as a therapeutic agent.

          -  Has a history of hypersensitivity or allergies to other fXa inhibitors.

          -  Has received any investigational compound within 30 days prior to Screening or is
             currently participating in another study which entails the administration of an
             investigational or marketed drug, supplement or intervention including, but not
             limited to diet, exercise, lifestyle or invasive procedure.

          -  Is required to take or intends to continue taking any disallowed medication, any
             prescription medication, herbal treatment or over-the counter medication that may
             interfere with evaluation of the study medication, including:

               -  azole antifungal agents

               -  cyclosporine

               -  clarithromycin

               -  HIV protease inhibitors

               -  nefazodone

               -  ritonavir

               -  quinidine

               -  amiodarone

               -  verapamil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Executive Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pensecola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Algere</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haskovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pazardjik</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Silistra</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chilliwack</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Charles Borromée</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Langen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Székesfehérvár</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bikaner</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calicut</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mangalor</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimoga</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thrissur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trivandrum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vadodara</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeonrabukdo</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hardenberg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bacau</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baia Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Braila</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suceava</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targoviste</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Voronezh</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kamenica</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sremska</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>CapeTown</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goodwood</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parow</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pinelands</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Randburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Airdrie</city>
        <state>North Lanarkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2008</study_first_posted>
  <disposition_first_submitted>March 13, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>March 13, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 13, 2016</disposition_first_posted>
  <last_update_submitted>March 13, 2016</last_update_submitted>
  <last_update_submitted_qc>March 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unstable Angina</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Thrombolysis</keyword>
  <keyword>Anticoagulant</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>1-(1-(3-((6-chloronaphthalen-2-yl)sulfonyl)-2-hydroxypropanoyl)piperidin-4-yl)tetrahydropyrimidin-2(1H)-one</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

